NeoGenomics : Investor Presentation – April 2025
NEO
1Q 2025
Financial Results
Nasdaq: NEO
1
April 29, 2025
Mission
We save lives by improving patient care.
Vision
3
We are becoming the world's leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services.
1Q 2025 Highlights
Testing volumes increased 8% vs prior year
Adjusted Gross Margin increased to 47%
18% growth in Clinical NGS revenue
AEBITDA improves 102% with 7 consecutive quarters of positive AEBITDA
301
312
315
322
Clinical Volume (unit thousands)
326
$447
$454
$463
$465
Clinical Revenue Per Test
$459
Announced acquisition of Pathline to strengthen commercial presence in the Northeast
Submitted PanTracer LBx to MolDx
Q1'24 Q2'24 Q3'24 Q4'24 Q1'25
Revenues ($millions)
$172.0
Q1'24 Q2'24 Q3'24 Q4'24 Q1'25
Adj. EBITDA ($millions)
$13.4
$11.9
Aligned commercial and operations team under President and COO
$164.5
$167.8
$168.0
$10.9
$7.1
$156.2
$3.5
Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25
Quarterly financial information is unaudited. Growth corresponds to prior year period. Reference non-GAAP reconciliation slides in Appendix for details. 4
Sustainable Growth - Clinical
8% YoY
Up to 140 reps
Pathline Acquisition
Clinical NGS grew 18%
Approx. 31% of total Clinical revenue
5 of our recently launched NGS tests account for 22% of total Clinical revenue
Focused on Community Oncology
Timing aligns with new product launches
EPIC Partnership to Accelerate Integration
Roll out in 2H'25
Adaptive MRD Partnership
Expanding offering across care continuum
Expands Reach to Northeast Region
Targeted approach into #3 cancer market in US
Improves TAT for region
5
Disclaimer
NeoGenomics Inc. published this content on April 29, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 29, 2025 at 12:40 UTC.